CG Oncology, Inc. Common stock CGON

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

• Zacks Investment Research 8 sept

  Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

  The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed healthcare ETF that tracks small-cap and mid-cap pharmaceutical and biotechnology stocks in Phase II or Phase III FDA clinical trials. With a 0.5% expense ratio, $243.54 million in assets, and 107 holdings, it has delivered 32.1% year-to-date returns and 82.83% over 12 months. However, it carries high risk with a beta of 0.74 and 30.54% standard deviation. The fund received a Zacks ETF Rank of 3 (Hold), with alternatives like VHT and XLV offering lower expense ratios.

  

• GlobeNewswire Inc. 2 sept

  CG Oncology to Present at Upcoming Investor Conferences in September

  CG Oncology announced that its CEO Arthur Kuan will participate in fireside chat presentations at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, and the Morgan Stanley Global Healthcare Conference on September 14, 2026. The company is a late-stage clinical biopharmaceutical firm developing immunotherapies for bladder cancer treatment.

  

• GlobeNewswire Inc. 29 jul

  Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

  Kuehn Law is investigating whether officers and directors of CG Oncology, Inc. breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is seeking shareholders to participate in the investigation at no cost.

  

• GlobeNewswire Inc. 27 jul

  CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

  CG Oncology announced publication of Phase 3 BOND-003 Cohort C trial results for cretostimogene grenadenorepvec in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The study demonstrated 75.5% complete response rates, median duration of response of 27.9 months, 89% bladder preservation at 12 months, and a favorable safety profile with no Grade 3+ adverse events.